Akero Therapeutics Inc AKRO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:35 AM EDT
20.66quote price arrow up+0.15 (+0.73%)
Volume
13,666
52 week range
11.25 - 58.38
Loading...
  • Open20.44
  • Day High20.70
  • Day Low20.39
  • Prev Close20.51
  • 52 Week High58.38
  • 52 Week High Date06/13/23
  • 52 Week Low11.25
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap1.413B
  • Shares Out68.40M
  • 10 Day Average Volume0.69M
  • Dividend-
  • Dividend Yield-
  • Beta-0.29
  • YTD % Change-12.16

KEY STATS

  • Open20.44
  • Day High20.70
  • Day Low20.39
  • Prev Close20.51
  • 52 Week High58.38
  • 52 Week High Date06/13/23
  • 52 Week Low11.25
  • 52 Week Low Date10/27/23
  • Market Cap1.413B
  • Shares Out68.40M
  • 10 Day Average Volume0.69M
  • Dividend-
  • Dividend Yield-
  • Beta-0.29
  • YTD % Change-12.16

RATIOS/PROFITABILITY

  • EPS (TTM)-2.85
  • P/E (TTM)-7.24
  • Fwd P/E (NTM)-4.92
  • EBITDA (TTM)-172.841M
  • ROE (TTM)-35.22%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)4.66%

EVENTS

  • Earnings Date05/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Akero Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY...
Mark Iwicki
Independent Chairman of the Board
Andrew Cheng M.D., Ph.D.
President, Chief Executive Officer, Director
William White J.D.
Chief Financial Officer, Executive Vice President, Head of Corporate Development, Treasurer
Address
601 Gateway Boulevard, Suite 350
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
EWTX
Edgewise Therapeutics Inc
15.45UNCHUNCH
MORF
Morphic Holding Inc
27.74+0.23+0.84%
INBX
Inhibrx Inc
34.47+0.02+0.06%
SYRE
Spyre Therapeutics Inc
34.10-1.48-4.16%
TARS
Tarsus Pharmaceuticals Inc
32.88+0.03+0.09%